ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03352427
Recruitment Status : Recruiting
First Posted : November 24, 2017
Last Update Posted : July 23, 2018
Sponsor:
Information provided by (Responsible Party):
University of Michigan Cancer Center

November 20, 2017
November 24, 2017
July 23, 2018
November 17, 2017
December 1, 2024   (Final data collection date for primary outcome measure)
  • Proportion of patients alive without progression at 1 year [ Time Frame: 1 Year ]
    The primary endpoint is Progression Free Survival Rate (PFS). Progression will be defined as 25% increase in the size of the tumor or appearance of new lesions.
  • Proportion of patients alive without progression at 2 years [ Time Frame: 2 Years ]
    The primary endpoint is Progression Free Survival Rate (PFS). Progression will be defined as 25% increase in the size of the tumor or appearance of new lesions.
  • The proportion of patients that respond to treatment [ Time Frame: 56 Days ]
    The overall response assessment will take into account response in both target and non-target lesions, as well as the appearance of new lesions. Partial Response (PR) will be defined as ≥50% decrease in size of tumor in comparison to baseline measurements. Complete Response (CR) will be defined as The disappearance of all abnormal signal. This includes return to normal size of the brainstem for brainstem lesions.
Same as current
Complete list of historical versions of study NCT03352427 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations
A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR/FGFR Alterations
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR or FGFR alterations.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Glioma
  • Drug: Dasatinib
    60 mg/m2 orally twice daily
  • Drug: Everolimus
    3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
Experimental: Dasatinib+Everolimus

Dasatinib = 60 mg/m2 orally twice daily

Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml

Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles.

Interventions:
  • Drug: Dasatinib
  • Drug: Everolimus
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
32
Same as current
December 1, 2025
December 1, 2024   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological confirmation of a newly diagnosed high-grade glioma or DIPG (Stratum A)
  • Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG) (Stratum B)
  • Participants must have a genomic (DNA and/or RNA) alteration (mutation, fusion, and/or amplification) involving PDGF-A, PDGF-B, PDGFR-A, PDGFR-B, FGF1, FGF3, FGFR1 or FGFR3, as identified by tumor sequencing.
  • Age at enrollment: Greater than 1 year and less than 30 years
  • BSA (body surface area): BSA greater than 0.3 m2
  • Karnofsky (Measure of performance for cancer patients where 100% represents perfect health) > 50% for patients > 16 years of age and Lansky (Measure of performance for pediatric cancer patients where 100% represents perfect health) > 50% for patients < 16 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Adequate bone marrow function
  • Adequate liver function
  • Adequate renal and metabolic function
  • Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
  • No increase in steroid dose within the past 7 days
  • Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions.
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy.
  • Myelosuppressive chemotherapy: Must not have received within 3 weeks.
  • Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting.
  • Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy.
  • ≥ 12 weeks must have elapsed from craniospinal radiation; ≥ 2 weeks must have elapsed from focal radiation.
  • > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team.
  • Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed.
  • All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents.

Exclusion Criteria:

  • Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded.
  • Patients with uncontrolled infection are excluded.
  • Patients with known bleeding disorders or more than punctate intratumoral hemorrhage are excluded.
  • Patients receiving other anti-neoplastic agents are excluded.
  • Patients on enzyme-inducing anticonvulsive agents are excluded
  • Patients requiring strong CYP3A4 or PGP inducers or inhibitors are excluded (verapamil, diltiazem, aprepitant, voriconazole, posaconazole, fluconazole (higher dose), phenytoin, carbamazepine, phenobarbital, (levetiracetam is ok), rifampin, rifabutin).
  • Patients requiring anticoagulation or with uncontrolled bleeding are excluded.
  • Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment.
  • Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded.
  • Previous hypersensitivity to rapamycin or rapamycin derivatives
Sexes Eligible for Study: All
1 Year to 30 Years   (Child, Adult)
No
Contact: Carl Koschmann, M.D. 734-936-9814 ckoschma@med.umich.edu
United States
 
 
NCT03352427
UMCC 2017.042
HUM00123094 ( Other Identifier: University of Michigan )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
University of Michigan Cancer Center
University of Michigan Cancer Center
Not Provided
Principal Investigator: Carl Koschmann, M.D. University of Michigan Cancer Center
University of Michigan Cancer Center
July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP